GLP-1ScienceWhy Women With Type 2 Diabetes Are Diagnosed Later Than MenBy Lori YoumshajekianBusinessBlocked From Selling Off-Brand Ozempic, Telehealth Startups Embrace a Less Effective DrugBy Kate KnibbsSciencePatients Are Left With Few Options as GLP-1 Copycats DisappearBy Emily Mullin and Kate KnibbsScienceDiabetes Is Rising in Africa. Could It Lead to New Breakthroughs?By David CoxBusinessEli Lilly Sues 4 GLP-1 Telehealth Startups, Escalating War on Knockoff DrugsBy Kate Knibbs and Emily MullinScienceThe Ozempic Shortage Is OverBy Kate Knibbs and Emily MullinScienceYour Love Life on OzempicBy Emily MullinThe Big StoryThe King of Ozempic Is Scared as HellBy Virginia HeffernanScienceThe Crackdown on Compounded GLP-1 Meds Has BegunBy Kate KnibbsScienceA Major GLP-1 Drug Shortage Is Over. Some Patients Aren’t CelebratingBy Kate KnibbsScienceThe Benefits of Ozempic Are MultiplyingBy Emily MullinScienceThe Race for the Next OzempicBy Emily MullinScienceIt’s Shockingly Easy to Buy Off-Brand Ozempic Online, Even if You Don’t Need ItBy Kate KnibbsScienceNot Everyone Loses Weight on OzempicBy Emily MullinScienceWhat the Scientists Who Pioneered Weight-Loss Drugs Want You to KnowBy Matt Reynolds
.jpg)
